Long-term side effects of growth hormone treatment in children with Prader–Willi syndrome

References

• Cassidy SB, Schwartz S, Miller JL, Driscoll DJ. Prader–Willi syndrome. Genet Med 2012;14:10-26
   PubMed Web of Science ®Google Scholar
• Eiholzer U, Bachmann S, l'Allemand D. Is there growth hormone deficiency in Prader–Willi Syndrome? Six arguments to support the presence of hypothalamic growth hormone deficiency in Prader–Willi syndrome. Horm Res 2000;53(Suppl 3):44-52
   PubMedGoogle Scholar
• Lindgren AC, Ritzén EM. Five years of growth hormone treatment in children with Prader–Willi syndrome. Swedish National Growth Hormone Advisory Group. Acta Paediatr Suppl 1999;88(433):109-11
   PubMedGoogle Scholar
• Myers SE, Carrel AL, Whitman BY, Allen DB. Physical effects of growth hormone treatment in children with Prader–Willi syndrome. Acta Paediatr Suppl 1999;88(433):112-14
   PubMedGoogle Scholar
• Bosio L, Beccaria L, Benzi F, et al. Body composition during GH treatment in Prader-Labhardt-Willi syndrome. J Pediatr Endocrinol Metab 1999;12(Suppl 1):351-3
   PubMedGoogle Scholar
• Myers SE, Carrel AL, Whitman BY, Allen DB. Sustained benefit after 2 years of growth hormone on body composition, fat utilization, physical strength and agility, and growth in Prader–Willi syndrome. J Pediatr 2000;137(1):42-9
   PubMed Web of Science ®Google Scholar
• Schmidt H, Bechtold S, Schwarz HP. Prader-Labhart-Willi syndrome: auxological response to a conventional dose of growth hormone in patients with classical growth hormone deficiency. Eur J Med Res 2000;5(7):307-10
   PubMedGoogle Scholar
• Carrel AL, Allen DB. Effects of growth hormone on body composition and bone metabolism. Endocrine 2000;12(2):163-72
   PubMedGoogle Scholar
• Eiholzer U, l'Allemand D. Growth hormone normalises height, prediction of final height and hand length in children with Prader–Willi syndrome after 4 years of therapy. Horm Res 2000;53(4):185-92
   PubMedGoogle Scholar
• Tauber M, Barbeau C, Jouret B, et al. Auxological and endocrine evolution of 28 children with Prader–Willi syndrome: effect of GH therapy in 14 children. Horm Res 2000;53(6):279-87
   PubMedGoogle Scholar
• Carrel AL, Myers SE, Whitman BY, Allen DB. Growth hormone improves body composition, fat utilization, physical strength and agility, and growth in Prader–Willi syndrome: a controlled study. J Pediatr 1999;134:215-21
   PubMed Web of Science ®Google Scholar
• Festen DA, de Lind van Wijngaarden R, van Eekelen M, et al. Randomized controlled GH trial: effects on anthropometry, body composition and body proportions in a large group of children with Prader–Willi syndrome. Clin Endocrinol (Oxf) 2008;69(3):443-51
   PubMed Web of Science ®Google Scholar
• Carrel AL, Myers SE, Whitman BY, et al. Long-term growth hormone therapy changes the natural history of body composition and motor function in children with Prader–Willi syndrome. J Clin Endocrinol Metab 2010;95(3):1131-6
   PubMedGoogle Scholar
• Bakker NE, Kuppens RJ, Siemensma EP, et al. Eight years of growth hormone treatment in children with Prader–Willi syndrome: maintaining the positive effects. J Clin Endocrinol Metab 2013;98(10):4013-22
   PubMedGoogle Scholar
• Whitman BY, Myers S, Carrel A, Allen D. The Behavioral Impact of Growth Hormone Treatment for Children and Adolescents With Prader–Willi Syndrome: a 2-Year, Controlled Study. Pediatrics 2002;109:e35
   PubMedGoogle Scholar
• Wang ED, Drummond DS, Dormans JP, et al. Scoliosis in patients treated with growth hormone. J Pediatr Orthoped 1997;17:708-11
   PubMedGoogle Scholar
• Eiholzer U, Nordmann Y, L’allemand D. Fatal outcome of sleep apnoea in PWS during the initial phase of growth hormone treatment. A case report. Horm Res 2002;58:24-6
   PubMedGoogle Scholar
• Nordmann Y, Eiholzer U, l’Allemand D, et al. Sudden death of an infant with Prader–Willi Sindrome – not a unique case? Biol Neonate 2002;82:139-41
   PubMedGoogle Scholar
• Van Vliet G, Deal CL, Crock PA, et al. Sudden death in growth hormone-treated children with Prader–Willi syndrome. J Pediatr 2004;144:129-31
   PubMed Web of Science ®Google Scholar
• Craig ME, Cowell CT, Larsson P, et al. International Board. Growth hormone treatment and adverse events in Prader–Willi syndrome: data from KIGS (the Pfizer International Growth Database). Clin Endocrinol (Oxf) 2006;65:178-85
   PubMed Web of Science ®Google Scholar
• Eiholzer U. Deaths in children with Prader–Willi syndrome. A contribution to the debate about the safety of growth hormone treatment in children with PWS. Horm Res 2005;63:33-9
   PubMedGoogle Scholar
• Grugni G, Livieri C, Corrias A, et al. Genetic Obesity Study Group of the Italian Society of Pediatric Endocrinology and Diabetology. Death during GH therapy in children with Prader–Willi syndrome: description of two new cases. J Endocrinol Invest 2005;28:554-7
   PubMedGoogle Scholar
• Nagai T, Obata K, Tonoki H, et al. Cause of sudden, unexpected death of Prader–Willi syndrome patients with or without growth hormone treatment. Am J Med Genet A 2005;136:45-8
   PubMedGoogle Scholar
• Riedl S, Blumel P, Zwiauer K, Frisch H. Death in two female Prader. Willi syndrome patients during the early phase of growth hormone treatment. Acta Paediatr 2005;94:974-7
   PubMedGoogle Scholar
• Sacco M, Di Giorgio G. Sudden death in Prader–Willi syndrome during growth hormone therapy. Horm Res 2005;63:29-32
   PubMedGoogle Scholar
• Bakker B, Maneatis T, Lippe B. Sudden death in Prader–Willi syndrome: brief review of five additional cases. Concerning the article by U. Eiholzer et al.: deaths in children with Prader–Willi syndrome. A contribution to the debate about the safety of growth hormone treatment in children with PWS (Horm Res 2005;63:33-39). Horm Res 2007;67(4):203-4
   PubMedGoogle Scholar
• Tauber M, Diene G, Molinas C, Hebert M. Review of 64 Cases of Death in Children With Prader–Willi Syndrome. Am J Med Genet Part A 2008;146:881-7
   PubMed Web of Science ®Google Scholar
• Herlitz H, Jonsson O, Bengtsson BA. Effect of recombinant human growth hormone on cellular sodium metabolism. Clin Sci 1994;86:233-7
   Web of Science ®Google Scholar
• Bozzola M, De Benedetti F, De Amici M, et al. Stimulating effect of growth hormone on cytokine release in children. Eur J Endocrinol 2003;149:397-401
   PubMedGoogle Scholar
• Berini J, Spica Russotto V, Castelnuovo P, et al. Genetic Obesity Study Group of the Italian Society of Pediatric Endocrinology and Diabetology (ISPED). Growth hormone therapy and respiratory disorders: long-term follow-up in PWS children. J Clin Endocrinol Metab 2013;98(9):E1516-23
   PubMed Web of Science ®Google Scholar
• Deal CL, Tony M, Höybye Hoybye. C, et al. the 2011 GH in PWS Clinical Care Guidelines Workshop Participants. Growth Hormone Research Society Workshop Summary: Consensus guidelines for recombinant human growth hormone therapy in Prader–Willi syndrome. J Clin Endocrinol Metab 2013;98:E1072-87
   PubMed Web of Science ®Google Scholar
• Salvatoni A, Berini J, Chiumello G, et al. POI: a score to modulate GH treatment in children with Prader–Willi syndrome. Horm Res Paediatr 2012;78(3):201-2
   PubMed Web of Science ®Google Scholar
• Nixon GM, Rodda CP, Davey MJ. Longitudinal association between growth hormone therapy and obstructive sleep apnea in a child with Prader–Willi syndrome. J Clin Endocrinol Metab 2011;96(1):29-33
   PubMed Web of Science ®Google Scholar
• Al-Saleh S, Al-Naimi A, Hamilton J, et al. Longitudinal evaluation of sleep-disordered breathing in children with Prader–Willi Syndrome during 2 years of growth hormone therapy. J Pediatr 2013;162(2):263-8
   PubMed Web of Science ®Google Scholar
• Odent T, Accadbled F, Koureas G, et al. Scoliosis in patients with Prader–Willi syndrome. Pediatrics 2008;122(2):e499-503
   Web of Science ®Google Scholar
• de Lind van Wijngaarden RF, de Klerk LW, Festen DA, et al. Randomized controlled trial to investigate the effects of growth hormone treatment on scoliosis in children with Prader–Willi syndrome. J Clin Endocrinol Metab 2009;94(4):1274-80
   PubMed Web of Science ®Google Scholar
• Nagai T, Obata K, Ogata T, et al. Growth hormone therapy and scoliosis in patients with Prader–Willi syndrome. Am J Med Genet A 2006;140(15):1623-7
   PubMedGoogle Scholar
• Murakami N, Obata K, Abe Y, et al. Scoliosis in Prader–Willi syndrome: effect of growth hormone therapy and value of paravertebral muscle volume by CT in predicting scoliosis progression. Am J Med Genet A 2012;158(7):1628-32
   Google Scholar
• Einfeld SL, Kavanagh SJ, Smith A, et al. Mortality in Prader–Willi syndrome. Am J Ment Retard 2006;111(3):193-8
   PubMedGoogle Scholar
• Brambilla P, Crinò A, Bedogni G, et al. Genetic Obesity Study Group of the Italian Society of Pediatric Endocrinology and Diabetology (ISPED). Metabolic syndrome in children with Prader–Willi syndrome: the effect of obesity. Nutr Metab Cardiovasc Dis 2011;21(4):269-76
   PubMedGoogle Scholar
• L’Allemand D, Eiholzer U, Schlumpf M, et al. Carbohydrate metabolism is not impaired after 3 year of growth hormone therapy in children with Prader–Willi Syndrome. Horm Res 2003;59:239-48
   PubMedGoogle Scholar
• Losa M, Scavini M, Gatti E, et al. Long-term effects of growth hormone replacement therapy on thyroid function in adults with growth hormone deficiency. Thyroid 2008;18(12):1249-54
   PubMedGoogle Scholar
• Behan LA, Monson JP, Agha A. The interaction between growth hormone and the thyroid axis in hypopituitary patients. Clin Endocrinol (Oxf) 2011;74(3):281-8
   PubMedGoogle Scholar
• Vaiani E, Herzovich V, Chaler E, et al. Thyroid axis dysfunction in patients with Prader–Willi syndrome during the first 2 years of life. Clin Endocrinol (Oxf) 2010;73:546-50
   PubMed Web of Science ®Google Scholar
• Festen DA, Visser TJ, Otten BJ, et al. Thyroid hormone levels in children with Prader–Willi syndrome before and during growth hormone treatment. Clin Endocrinol (Oxf) 2007;67:449-56
   PubMed Web of Science ®Google Scholar
• Jostel A, Rydert WDJ, Shalet SM. The use of thyroid function tests in the diagnosis of hypopituitarism: definition and evaluation of the TSH Index. Clin Endocrinol (Oxf) 2009;71:529-34
   PubMed Web of Science ®Google Scholar
• de Lind van Wijngaarden RF, Otten BJ, Festen DA, et al. High prevalence of central adrenal insufficiency in patients with Prader–Willi syndrome. J Clin Endocrinol Metab 2008;93(5):1649-54
   PubMed Web of Science ®Google Scholar
• Corrias A, Grugni G, Crinò A, et al. Study Group for Genetic Obesity of Italian Society of Pediatric Endocrinology and Diabetology (SIEDP/ISPED). Assessment of central adrenal insufficiency in children and adolescents with Prader–Willi syndrome. Clin Endocrinol (Oxf) 2012;76(6):843-50
   PubMedGoogle Scholar
• Farholt S, Sode-Carlsen R, Christiansen JS, et al. Normal cortisol response to high-dose synacthen and insulin tolerance test in children and adults with Prader–Willi syndrome. J Clin Endocrinol Metab 2011;96(1):E173-80
   Web of Science ®Google Scholar
• Giavoli C, Bergamaschi S, Ferrante E, et al. Effect of growth hormone deficiency and recombinant hGH (rhGH) replacement on the hypothalamic-pituitary-adrenal axis in children with idiopathic isolated GH deficiency. Clin Endocrinol (Oxf) 2008;68(2):247-51
   PubMedGoogle Scholar
• Moore JS, Monson JP, Kaltsas G, et al. Modulation of 11beta-hydroxysteroid dehydrogenase isozymes by growth hormone and insulin-like growth factor: in vivo and in vitro studies. J Clin Endocrinol Metab 1999;84(11):4172-7
   PubMedGoogle Scholar
• de Lind van Wijngaarden RF, Joosten KF, van den Berg S, et al. The relationship between central adrenal insufficiency and sleep-related breathing disorders in children with Prader–Willi syndrome. J Clin Endocrinol Metab 2009;94(7):2387-93
   PubMedGoogle Scholar
• Samani AA, Yakar S, Le Roith D, Brodt P. The role of the IGF system in cancer growth and metastasis: overview and recent insights. Endocr Rev 2007;20-47
   PubMedGoogle Scholar
• Corrias A, Bellone J, Beccaria L, et al. GH/IGF-I axis in Prader–Willi syndrome: evaluation of IGF-I levels and of the somatotroph responsiveness to various provocative stimuli. Genetic Obesity Study Group of Italian Society of Pediatric Endocrinology and Diabetology. J Endocrinol Invest 2000;23(2):84-9
   PubMed Web of Science ®Google Scholar
• Davies HD, Leusink GL, McConnell A, et al. Myeloid leukemia in Prader–Willi syndrome. J Pediatr 2003;142(2):174-8
   PubMedGoogle Scholar
• Chapman EJ, Knowles MA. Necdin: a multi functional protein with potential tumor suppressor role? Mol Carcinog 2009;48(11):975-81
   PubMedGoogle Scholar
• Asai T, Liu Y, Di Giandomenico S, et al. Necdin, a p53 target gene, regulates the quiescence and response to genotoxic stress of hematopoietic stem/progenitor cells. Blood 2012;120(8):1601-12
   PubMedGoogle Scholar
• Crock PA, McKenzie JD, Nicoll AM, et al. Benign intracranial hypertension and recombinant growth hormone therapy in Australia and New Zealand. Acta Paediatr 1998;87(4):381-6
   PubMed Web of Science ®Google Scholar
• Price DA, Clayton PE, Lloyd IC. Benign intracranial hypertension induced by growth hormone treatment. Lancet 1995;345(8947):458-9
   PubMed Web of Science ®Google Scholar
• Babikian P, Corbett J, Bell W. Idiopathic intracranial hypertension in children: the Iowa experience. J Child Neurol 1994;9(2):144-9
   PubMed Web of Science ®Google Scholar
• Darendeliler F. Safety of growth hormone treatment. J Clin Res Ped Endo 2009;(Suppl 1):36-43
   Google Scholar
• Rappaport EB, Fife D. Slipped capital femoral epiphysis in growth hormone-deficient patients. Am J Dis Child 1985;139:396-9
   PubMedGoogle Scholar
• Blethen SL, Rundle AC. Slipped capital femoral epiphysis in children treated with growth hormone. A summary of the National Cooperative Growth Study Experience. Horm Res 1996;46:113-16
   PubMed Web of Science ®Google Scholar
• Clayton PE, Cowell CT. Safety issues in children and adolescents during growth hormone therapy- a review. Growth Horm IGF Res 2000;10:306-17
   PubMedGoogle Scholar
• Wilton P. Adverse events reported in KIGS . In: Ranke MB, Price DA, Reiter EO, editors, Growth hormone therapy in pediatrics: 20 years of KIGS. Karger; Basel: 2007. p. 432-41
   Google Scholar
• Carel JC, Ecosse E, Landier F, et al. Long-term mortality after recombinant growth hormone treatment for isolated growth hormone deficiency or childhood short stature: preliminary report of the French SAGhE study. J Clin Endocrinol Metab 2012;97(2):416-25
   PubMedGoogle Scholar
• Blethen SL, Allen DB, Graves D, et al. Safety of recombinant deoxyri- bonucleic acid-derived growth hormone; the National Cooperative Growth Study experience. J Clin Endocrinol Metab 1996;81:1704-10
   PubMedGoogle Scholar
• Maneatis T, Baptista J, Connelly K, Blethen S. Growth hormone safety update from the National Cooperative Growth Study. J Pediatr Endocrinol Metab 2000;13(Suppl 2):1035-44
   PubMedGoogle Scholar
• Zadik Z, Estrov Z, Karov Y, et al. The effect of growth hormone and IGF-I on clonogenic growth of hematopoietic cells in leukemic patients during active disease and during remission - a preliminary report. J Pediatr Endocrinol 1993;6:79-83
   PubMedGoogle Scholar
• Chan JM, Stampfer MJ, Giovannucci E, et al. Plasma insulin-like growth factor -I and prostate cancer risk: a prospective study. Science 1998;279:563-6
   PubMed Web of Science ®Google Scholar
• Wilton P. Safety of growth hormone value of a large database. Clin Pediatr Endocrinol 1994;3(Suppl 5):61-71
   Google Scholar
• Ergun-Longmire B, Mertens AC, Mitby P, et al. Growth hormone treatment and risk of second neoplasms in the childhood cancer survivor. J Clin Endocrinol Metab 2006;91:3494-8
   PubMed Web of Science ®Google Scholar
• Swerdlow AJ, Higgins CD, Adlard P, Preece MA. Risk of cancer in patients treated with human pituitary growth hormone in the UK. 1959-1985: a cohort study. Lancet 2002;360:273-7
   PubMed Web of Science ®Google Scholar